LA JOLLA PHARMACEUTICAL CO
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|---|---|
| Revenue | $75.7M | $33.4M | $23.1M | $10.1M | $0 | $0 |
| Operating income | $21.8M | −$35.8M | −$109.8M | −$194.1M | −$115.4M | −$78.4M |
| Net income | $19.7M | −$39.4M | −$116.5M | −$199.5M | −$114.8M | −$78.2M |
| Total assets | $101.2M | $72.2M | $132.2M | $204.3M | $119.5M | $70.8M |
| Total liabilities | $168.0M | $160.3M | $188.2M | $168.4M | $31.3M | $9.8M |
| Equity | −$66.7M | −$88.1M | −$56.0M | $35.9M | $88.2M | $61.0M |
| EPS (diluted) | $0.58 | $-1.44 | — | — | — | — |
| Shares out. | 27.4M | 27.2M | 27.1M | 22.2M | 18.3M | 18.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- 28.8%
- Net margin
- 26.0%
- Return on equity
- −29.5%
- Return on assets
- 19.4%
- Return on capital (ROCE)
- 26.1%
- Liabilities / assets
- 165.9%
- Debt / equity
- —
- Book value / share
- $-2.43
- Revenue growth (YoY)
- 126.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- -29.79distress
- Accruals / assets
- −8.5%clean
- Piotroski F-Score
- 8/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 1 warning● 4 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2012
- NT 10-Kmissed a reporting deadline ↗Mar 30, 2011
- NT 10-Qmissed a reporting deadline ↗Aug 16, 2010
- NT 10-Qmissed a reporting deadline ↗May 12, 2010
- NT 10-Kmissed a reporting deadline ↗Mar 29, 2010
- NT 10-Qmissed a reporting deadline ↗Nov 9, 2009
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ramsay David ADirector | Aug 22, 2022 | D | 100,000 | $6.23 |
| Tang Kevin CDirector | Aug 22, 2022 | U | 9.6M | $6.23 |
| Edwards Larry G.Officer — Chief Executive Officer | Aug 22, 2022 | D | 11,969 | $6.23 |
| Johnson Laura L.Director | Aug 22, 2022 | D | 500 | $6.23 |
| Johnson Craig ADirector | Aug 22, 2022 | D | 12,000 | $6.23 |
| Hearne Michael SOfficer — Chief Financial Officer | Aug 22, 2022 | D | 10,186 | $6.23 |
| Tang Kevin CDirector | Aug 22, 2022 | U | 9.6M | $6.23 |
| Johnson Craig ADirector | Jul 8, 2022 | Option exercise | 12,000 | $3.93 |
| Hearne Michael SOfficer — Chief Financial Officer | Jun 30, 2022 | Grant | 236 | $2.71 |
| Hearne Michael SOfficer — Chief Financial Officer | Jun 15, 2022 | Grant | 236 | $2.72 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsAug 22, 2022
- Entered a material agreement · Other material eventJul 11, 2022
- Other material eventFeb 16, 2022
- Other material eventNov 18, 2021
- Shareholder voteJul 27, 2021
- Entered a material agreementJan 12, 2021
- Terminated a material agreementDec 18, 2020
- Changed auditorNov 5, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ALA JOLLA PHARMACEUTICAL COMPANYFeb 14, 2023
- 15-12GFORM 15Sep 1, 2022
- SC 13D/AAug 29, 2022
- SC 13DAug 29, 2022
- 4FORM 4 SUBMISSIONAug 24, 2022
- 4FORM 4 SUBMISSIONAug 24, 2022
- 4FORM 4 SUBMISSIONAug 24, 2022
- 4FORM 4 SUBMISSIONAug 24, 2022
- 4FORM 4 SUBMISSIONAug 24, 2022
- 4FORM 4 SUBMISSIONAug 24, 2022
- 4FORM 4 SUBMISSIONAug 24, 2022
- 4FORM 4 SUBMISSIONAug 24, 2022
- 4FORM 4 SUBMISSIONAug 24, 2022
- SC 13D/AAMENDMENT NO. 19Aug 24, 2022
- S-8 POSS-8 POS 333-227819Aug 23, 2022
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.